Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zavegepant - Pfizer

Next Previous
Drug Profile

Zavegepant - Pfizer

Alternative Names: BHV 3500; BMS-742413; BMS-742413-03; PF 07930207; Vazegepant; Vazegepant - Pfizer; Zavegepant hydrochloride; ZAVZPRET

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Pfizer
  • Class Anti-infectives; Antiallergics; Antimigraines; Indazoles; Piperazines; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II/III COVID-19 respiratory infection
  • No development reported Allergic asthma

Most Recent Events

  • 16 Jun 2025 Pfizer completes a phase III trial in Migraine in China, Taiwan, South Korea (Intranasal) (NCT05989048)
  • 19 May 2025 Pfizer plans a phase I trial for Migraine (In children) in USA (Intranasal, Spray) in May 2025 (NCT06995729)
  • 16 May 2025 Phase-I clinical trials in Migraine (In children) in USA (Intranasal) (NCT06995729)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top